These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 14642970

  • 1. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
    Möller HJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
    [Abstract] [Full Text] [Related]

  • 2. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

  • 3. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [Abstract] [Full Text] [Related]

  • 4. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y.
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [Abstract] [Full Text] [Related]

  • 5. From pharmacological profiles to clinical outcomes.
    Kerwin R.
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S1-4. PubMed ID: 11252517
    [Abstract] [Full Text] [Related]

  • 6. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 7. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol.
    de Bartolomeis A, Marmo F, Buonaguro EF, Rossi R, Tomasetti C, Iasevoli F.
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1516-29. PubMed ID: 23357084
    [Abstract] [Full Text] [Related]

  • 8. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS.
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [Abstract] [Full Text] [Related]

  • 9. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S.
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [Abstract] [Full Text] [Related]

  • 10. Amisulpride: from animal pharmacology to therapeutic action.
    Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H.
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
    [Abstract] [Full Text] [Related]

  • 11. [Flupenthixol--a partial atypical neuroleptic?].
    Kühn KU, Meyer K, Maier W.
    Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S38-41. PubMed ID: 10907612
    [Abstract] [Full Text] [Related]

  • 12. [The place of amisulpride in the atypical neuroleptic class].
    Perrault G, Schoemaker H, Scatton B.
    Encephale; 1996 Jun; 22 Spec No 2():3-8. PubMed ID: 8767034
    [Abstract] [Full Text] [Related]

  • 13. Amisulpride treatment for clozapine-induced sialorrhea.
    Praharaj SK, Sarkar S, Sinha VK.
    J Clin Psychopharmacol; 2009 Apr; 29(2):189-90. PubMed ID: 19512987
    [No Abstract] [Full Text] [Related]

  • 14. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ, Regenbogen B, Sachse J, Eich FX, Härtter S, Hiemke C.
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [Abstract] [Full Text] [Related]

  • 15. [New antipsychotic agents: new paths of research on the notion of atypical agents].
    Gosselin O, Di Scala G, Ribeyre JM, Kahn JP.
    Encephale; 1996 Dec; 22 Spec No 6():3-6. PubMed ID: 9102317
    [Abstract] [Full Text] [Related]

  • 16. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.
    J Med Chem; 2004 Jan 01; 47(1):143-57. PubMed ID: 14695828
    [Abstract] [Full Text] [Related]

  • 17. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.
    Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G.
    Hum Psychopharmacol; 2002 Jan 01; 17(1):1-13. PubMed ID: 12404702
    [Abstract] [Full Text] [Related]

  • 18. Clinical implications of dopamine research in schizophrenia.
    Pani L.
    Curr Med Res Opin; 2002 Jan 01; 18 Suppl 3():s3-7. PubMed ID: 12418605
    [Abstract] [Full Text] [Related]

  • 19. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P.
    Synapse; 2006 Dec 01; 60(7):543-52. PubMed ID: 16952163
    [Abstract] [Full Text] [Related]

  • 20. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP, Perry CM.
    Drugs; 2001 Dec 01; 61(14):2123-50. PubMed ID: 11735643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.